BackgroundWhile endovascular thrombectomy (EVT) is firmly established for large vessel occlusion stroke, recent enthusiasm for extending EVT to distal medium vessel occlusions (DMVOs) has been tempered by the neutral results of three major randomized controlled trials: DISTAL, ESCAPE-MeVO, and DISCOUNT.ObjectiveTo critically examine why EVT failed to demonstrate benefit in DMVO trials, assess the associated procedural and clinical challenges, and explore potential future directions for safe and effective treatment in distal cerebrovascular territories.MethodsThis review synthesizes the key findings of recent DMVO thrombectomy trials and contextualizes them within the anatomical, technical, and clinical limitations specific to distal interventions. It further highlights innovations of devices and distal EVT techniques as possible solutions.FindingsThe trials showed no functional benefit of EVT over best medical therapy for unselected DMVO patients and raised safety concerns, including partially increased rates of symptomatic intracranial hemorrhage and mortality in the EVT arms. Contributing factors include the fragility and tortuosity of distal vessels, suboptimal device compatibility, variability in operator experience, and potential limitations in imaging and patient selection. Preliminary data suggest that refined techniques may mitigate risks in very distal occlusions.ConclusionsRoutine EVT for DMVO stroke cannot be recommended based on current evidence. Future research must prioritize patient stratification, dedicated distal devices, and procedural innovation to safely extend thrombectomy into distal territories.
Sporns et al. (Thu,) studied this question.